US and UK Announce Tariff-Free Agreement on Drugs.

The United Kingdom and the United States have finalized a important bilateral deal that will maintain no duties on British drug products entering the US market.

Key Provisions of the Deal

In exchange for the tariff guarantee, the UK has committed to raise expenditure on medicines through the National Health Service (NHS). This move secures that tariffs on these crucial products will remain at nothing for a timeframe of 36 months.

This deal is in response to recent statements to dramatically increase duties on branded drug imports, with potential rates discussed reaching double the cost.

"This agreement between the UK reinforces the worldwide climate for innovative medicines and establishes much-needed fairness to U.S.–U.K. drug exports," a release said.

Trade Importance

Drugs are one of the Britain's largest export categories to the America, which is easily the largest market for leading UK drugmakers.

Statistics indicate that in the 12 months to the end of last September, the UK shipped pharmaceutical products totaling £11.1bn to the US. This amount accounted for nearly one-fifth of all goods exports in that timeframe.

"This guarantee secures work, boosts investment and facilitates the UK to emerge as a global hub for medical research," a government official stated.

Key NHS Changes

The agreement entails several specific pledges from the United Kingdom:

• Price Threshold Increase: The UK will lift the price threshold at which it judges new treatments to be prohibitively costly by 25%.
• Increased NHS Spending: There is a aim to raise total health service expenditure on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
• Refund Ceiling: The amount drug companies must refund to the NHS to control costs will be limited at 15%. In the past, repayments exceeded 20%.

Broader Context

The deal follows a ongoing row between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption.

The disagreement were exacerbated by assertions that US patients were paying a premium for the same drugs than people in the Britain and the EU.

Recently, several major pharmaceutical investments in the UK have been delayed or scrapped, while major funding commitments have been pledged toward American operations.

The Science Minister acknowledged that the NHS must invest a greater share on drugs, noting that its expenditure on drugs had decreased as a share of its total funding over the previous ten-year period.